Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Mauna Kea Technologies's EV-to-EBIT or its related term are showing as below:
FRA:1MK'
s EV-to-EBIT Range Over the Past 10 Years
Min: -17.34 Med: -4.24 Max: 3.19
Current: 3.08
During the past 13 years, the highest EV-to-EBIT of Mauna Kea Technologies was 3.19. The lowest was -17.34. And the median was -4.24.
FRA:1MK's EV-to-EBIT is ranked better than 94.61% of 482
companies
in the Medical Devices & Instruments industry
Industry Median: 17.95
vs FRA:1MK: 3.08
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Mauna Kea Technologies's Enterprise Value for the quarter that ended in Dec. 2025 was €14.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mauna Kea Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €14.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Mauna Kea Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mauna Kea Technologies EV-to-EBIT vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Mauna Kea Technologies's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Mauna Kea Technologies's EV-to-EBIT falls into.
Mauna Kea Technologies's current Enterprise Value is €36.31 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Mauna Kea Technologies's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €14.31 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mauna Kea Technologies (FRA:1MK) has a EV-to-EBIT of 2.54 as of Sep. 21, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Mauna Kea Technologies and its competitors. According to the industry distribution chart, Mauna Kea Technologies ranks #26 out of 482 companies in the Medical Devices & Instruments industry, placing it in the top 5.4%.
Is Mauna Kea Technologies' EV-to-EBIT too high?
Mauna Kea Technologies' current EV-to-EBIT is 2.54. The Medical Devices & Instruments industry median EV-to-EBIT is 17.95. Mauna Kea Technologies' value of 2.54 is 85.8% below this industry median. Based on the distribution chart, Mauna Kea Technologies ranks #26 out of 482 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Mauna Kea Technologies has a GF Score™ of 39/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Mauna Kea Technologies' EV-to-EBIT compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Mauna Kea Technologies ranks #26 out of 482 companies for EV-to-EBIT. This places Mauna Kea Technologies in the top 5% of its industry — outperforming the majority of peers. The industry median EV-to-EBIT is 17.95. Mauna Kea Technologies' value of 2.54 is 85.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Medical Devices & Instruments company?
The median EV-to-EBIT among Medical Devices & Instruments companies is 17.95, based on 482 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mauna Kea Technologies's current EV-to-EBIT of 2.54 is 85.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Mauna Kea Technologies and its competitors. For the Medical Devices & Instruments industry, the median EV-to-EBIT is 17.95 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mauna Kea Technologies's current EV-to-EBIT is 2.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mauna Kea Technologies stock overvalued right now?
Based on GuruFocus' analysis, Mauna Kea Technologies (FRA:1MK) is currently considered Fairly Valued. The stock's GF Value™ is €0.13, compared to a current price of €0.13 — trading 3.5% above its estimated fair value. The current EV-to-EBIT is 2.54 and 85.8% below the Medical Devices & Instruments industry median of 17.95. Mauna Kea Technologies' overall GF Score™ is 39/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Mauna Kea Technologies (FRA:1MK), the current EV-to-EBIT is 2.54 as of Sep. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Mauna Kea Technologies (FRA:1MK) Overvalued in 2026?
Based on GuruFocus' analysis, Mauna Kea Technologies stock appears to be overvalued.
The current stock price of €0.13 is trading 3.5% above its estimated GF Value™ of €0.13.
GuruFocus considers Mauna Kea Technologies to be Fairly Valued.
Key valuation signals for FRA:1MK:
EV-to-EBIT: 2.54
GF Value™: €0.13 vs. price of €0.13 (3.5% above fair value)
Industry Position: 85.8% below the Medical Devices & Instruments median (#26 of 482)
No single metric tells the full story. See the FRA:1MK stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Mauna Kea Technologies SA is a medical device company that develops, manufactures and markets an imaging platform for visualizing tissue at the cellular level, in real time, during standard procedures, with the mission of eliminating uncertainties in diagnosis and treatment through direct visualization of tissue in vivo at the microscopic level. The company's flagship product, Cellvizio, is the smallest microscope, designed for direct use during minimally invasive procedures. It operates in a single business segment: endomicroscopy. Its geographical presence includes EMEA (Europe, Middle East, Africa), USA and Canada, and Asia, of which the majority of the revenue is generated from USA and Canada.
39GF Score
Get the complete analysis for FRA:1MK
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1MK has been successfully added to your 
